TribLIVE

| Business

 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Generic drugmaker Mylan completes $1.75B acquisition in India

Email Newsletters

Click here to sign up for one of our email newsletters.

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

'American Coyotes' Series

Traveling by Jeep, boat and foot, Tribune-Review investigative reporter Carl Prine and photojournalist Justin Merriman covered nearly 2,000 miles over two months along the border with Mexico to report on coyotes — the human traffickers who bring illegal immigrants into the United States. Most are Americans working for money and/or drugs. This series reports how their operations have a major impact on life for residents and the environment along the border — and beyond.

Thursday, Dec. 5, 2013, 12:01 a.m.
 

Generic drugmaker Mylan Inc. expanded its global manufacturing capability and portfolio of injectable medications with a $1.75 billion acquisition on Wednesday.

Cecil-based Mylan, one of the world's biggest generic pharmaceutical companies, said it completed the purchase of the Agila unit of Indian drugmaker Strides Arcolab Ltd.

The deal, first announced in February, gives Mylan 13 manufacturing plants in six countries and four research and development centers staffed by 400 scientists.

The addition of Agila's portfolio means Mylan offers more than 1,200 injectable drugs across the world, with another 900 products awaiting regulatory approvals, the company said.

Agila's foothold in several emerging markets, including Brazil, India and Southeast Asia, was attractive to Mylan.

“The acquisition of Agila will create a global injectables leader, expanding and strengthening Mylan's existing injectables platform and portfolio, and providing Mylan entry into exciting, new geographic markets,” CEO Heather Bresch said in a statement. “We believe we can generate significant growth from this business.”

Mylan will hold back $250 million in the deal on the condition that Agila satisfy U.S. regulators over problems of one of its Indian manufacturing plants.

In September, the Food and Drug Administration sent a so-called warning letter to Agila as a result of a June inspection at its Bangalore factory that turned up deficient procedures for preventing contamination of products.

Alex Nixon is a staff writer for Trib Total Media. He can be reached at 412-320-7928 or anixon@tribweb.com.

Add Alex Nixon to your Google+ circles.

Subscribe today! Click here for our subscription offers.

 

 

 


Show commenting policy

Most-Read Business Headlines

  1. Cost-cutting at Kraft Heinz extends to refrigerator
  2. GNC to convert more stores to franchises as sales, profits slip
  3. Kennametal expects to consolidate plants as it shrinks manufacturing in continuing streamlining; profit drops
  4. Invasive beetle costs Pittsburgh-area power companies plenty
  5. Muni bond funds stressed
  6. U.S. asks Supreme Court to reinstate convictions of portfolio managers who won on appeal
  7. Home rental prices jumped again in June
  8. Range Resources cuts workforce 11%
  9. Economy’s 2Q best since last year
  10. PPG puts brand 1st in strategy to reach commercial paint market
  11. Travelers find direct Web route to Priory’s spirited past in North Side